Citations

Clear

1055 citation(s) found for "Small, J C".

844 Immune cell profile changes in patients treated with tarlatamab for extensive-stage small cell lung cancer in real world practice
Ma, Audrey, Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Karam, Dhauna , Potter, Ashley , Al‐Ajmi, Abdullah, Mina, Syeda A. , Taylor, Skyler, Parikh, Kaushal , Shanshal, Mohamed , Luce, A., Schwecke, Anna, Lin, Yi , Leventakos, Konstantinos , Taylor, Skyler J, Hazim, Antonious , Dimou, Anastasios , Molina, Julian, Mansfield, Aaron S. , Smith, Katherine E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A953-A954

10.1136/jitc-2025-sitc2025.0844 Get It

Abstract 4370186: Non-Bacterial Thrombotic Endocarditis and Intraventricular Small Vessel Thromboembolic Occlusion Mimicking ICI-Myocarditis in a Patient Treated with Pembrolizumab
Holthe, Jordan , Bois, Melanie C. , Bois, John P. , Sularz, Agata , Geske, Jeffrey B.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370186 Get It

Case Description: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with immune-related adverse events, including cardiovascular toxicity. While ICI-myocarditis is rare but potentially fatal, thrombotic complications—such as venous thromboembolism, arterial occlusion, and non-bacterial thrombotic endocarditis (NBTE)—are underrecognized. These raise questions about the roles of malignancy-associated hypercoagulability versus ICI-induced effects. We present a case of NBTE and myocardial microthrombi mimicking ICI-myocarditis. A 76-year-old woman with metastatic adenosquamous lung cancer and recent DVT (on apixaban and aspirin) presented with worsening dyspnea three weeks after starting pembrolizumab (Image 1). One week earlier, CT pulmonary angiography and coronary angiography were unrevealing. On presentation, she was stable but had peripheral edema, a late diastolic murmur, and elevated hs troponin (706→657→656 ng/L). NT-proBNP was 11,500 pg/mL. Cardiac MRI showed mid-wall late gadolinium enhancement (LGE), myocardial edema, and elevated T2 values—findings concerning for ICI-myocarditis. She initially improved on intravenous methylprednisolone. A week later, brain MRI showed multifocal embolic infarcts. Doppler ultrasound revealed a new left-sided DVT. TEE showed no intracardiac thrombus but identified a thickened aortic valve with moderate-to-severe regurgitation, a thickened mitral A2 segment with moderate regurgitation, and a patent foramen ovale (PFO) with left-to-right shunting. Findings raised concern for NBTE with systemic embolism or paradoxical embolism. Anticoagulation was transitioned to heparin, then warfarin. She was discharged on oral prednisone without further cancer therapy. Two months later, she died suddenly. Autopsy revealed fibrin-rich vegetations on the mitral valve consistent with NBTE and thromboembolic infarcts in small myocardial arteries, without inflammatory infiltrates or myocardial scarring (Image 2 and 3). Conclusion: This case highlights NBTE and microthrombi as important mimics of ICI-myocarditis. Despite MRI features suggestive of inflammation, pathology confirmed ischemic injury. ICIs have been suggested to promote thrombosis through elevated factor VIII, von Willebrand factor, reduced protein S, and systemic inflammation. Clinicians should consider thrombotic mimics in ICI-treated patients with cardiac symptoms and abnormal imaging. Tissue diagnosis may be necessary to guide management.
Distinct human small intestinal microbiome communities underlie visceral hypersensitivity in a humanized mouse model
Comba, Işın Y. , Sekhon, Prabhjot Kaur , Edwards, Brian S. , Willits, Adam , Shields‐Cutler, Robin , Bellampalli, Shreya S. , Mercado‐Perez, Arnaldo , Tienter, Dennis R., Till, Lisa , Farrugia, Gianrico, Kashyap, Purna , Louwies, Tijs, Mars, Ruben At, Bellampalli, Shreya, Mercado-Perez, Arnaldo, Smith-Edwards, Kristen M , Comba, Isin Y , Louwies, Tijs , Mars, Ruben A. , Xiao, Yang , Linden, David R. , Farrugia, Gianrico , Beyder, Arthur

Mayo Clinic

Journal of Clinical Investigation | October 23, 2025 | Volume: 135 | Issue: 24 | Pages: No page available

10.1172/jci190638 | PMID 41129263 Get It

Determinants of gastric emptying and transit in the small intestine
Malagelada, Juan‐R., Azpiroz, Fernando

Mayo Clinic

Comprehensive Physiology | October 23, 2025 | Volume: 1989 | Issue: 12S16 | Pages: 909-937

10.1002/j.2040-4603.1989.tb01309.x Get It

Abstract The sections in this article are: Functional Division of Stomach Methodological Aspects: Interrelationships Among Parietal Force and Manometric and Electrical Measurements of Gastric Motility Gastrointestinal Motility During Interdigestive Period Interdigestive Motor Pattern of Stomach Interrelationships Between Gastric Motility, Secretion, and Clearance of Duodenogastric Reflux During Interdigestive Period Gastrointestinal Response to A Meal Swallowing Early Postcibal Period Plateau Phase Declining Phase and Transition to Interdigestive Activity Gastric Emptying Profile Relationships among Gastric Emptying, Motility, and Structure: Mechanics of Gastric Emptying Preliminary Processing: Antropyloric Grinder Emptying Function Effects of Gravity and Body Position on Gastric Emptying Regulation of Gastric Emptying Physical and Chemical Characteristics of Meals That Influence their Emptying From Stomach Interactions Between Gastric Emptying and Gastric Secretion Intestinal Motility and its Relationship to Luminal Flow and Absorption Physiological Measurement of Transit In Small Bowel Effect of Opiates and Sex Hormones on Intestinal Motility and Transit Control of Gastrointestinal Motility: Physiological and Pathophysiological Implications for Gastric Motility and Intestinal Transit Control at Level of Gut Smooth Muscle Control at Level of Gut Intrinsic and Extrinsic Nervous Systems Hormonal Control Control at Cerebral Level
3D‐Printed Microfluidic Platform for Creating Porous Nanofibrous Microspheres to Regulate Cell Response and Enhance Tissue Regeneration (Small 41/2025)
Sharma, Navatha Shree , Killeen, Amy C., Reinhardt, Richard A., Lee, Dong-Hee , Tran, Huy Quang , Andrabi, Syed Muntazir , Yan, Zishuo , Zhu, Wuqiang , Xie, Jingwei

Mayo Clinic

Small | October 16, 2025 | Volume: 21 | Issue: 41 | Pages: No page available

10.1002/smll.70735 Get It

Regional anesthesia facilitates fistula creation over graft in patients with small-caliber veins: A single-center cohort
Alsabbagh, Yaman , Jlilati, Adeeb , Sarmiento, Joaquin, Lanka, Santh Prakash , Robards, Christopher B., Clendenen, Steven R. , Vandenberg, Jonathan , Jacobs, Christopher R. , Farres, Houssam , Ardon, Alberto E, Jacobs, Christopher, Jlilati, Adeeb , Erben, Young , Ardon, Alberto E. , Jacobs, Christopher

Mayo Clinic

The Journal of Vascular Access | October 8, 2025 | Volume: 27 | Issue: 3 | Pages: 1031-1037

10.1177/11297298251382268 | PMID 41058214 Get It

Objective: To evaluate the efficacy of regional anesthesia (RA) in enabling arteriovenous fistula (AVF) creation in patients with small-caliber veins who would typically receive arteriovenous grafts (AVG), and to compare access outcomes between AVF and AVG cohorts. Methods: We conducted a retrospective analysis of a prospectively maintained database from 2018 through 2024 involving patients with chronic kidney disease (CKD) requiring access creation. Eligible patients were those aged 18 years or older with inadequate veins for AVF creation based on initial ultrasound vein mapping. All patients underwent RA prior to the access creation and had a repeated intraoperative vein mapping at least 30 min after RA. Patients whose veins were sufficiently dilated and met the criteria for AVF creation underwent AVF formation; otherwise, an AVG was created. Outcomes included access maturation, patency rates, access failure, abandonment, and mortality. Statistical analysis was performed using R software, with significance set at p < 0.05. Results: Of the 106 patients, 67 (63.2%) underwent AVF creation post-RA due to sufficient vein dilation, while 39 (36.8%) received AVGs. Baseline vein diameters and comorbidities were comparable between groups. AVF maturation was achieved in 83.6% of AVF patients, with longer times to successful cannulation compared to AVG (median 187.0 vs 80.0 days, p = 0.037). Kaplan-Meier analysis revealed no difference in primary patency ( p = 0.97), but AVF patients had superior primary assisted ( p = 0.015) and secondary patency ( p = 0.033), and lower access failure rates ( p = 0.034) compared to AVG patients. Access abandonment and mortality rates did not differ significantly between groups. Conclusions: RA-induced venodilation enables the use of veins previously deemed inadequate for AVF creation, leading to improved access outcomes compared to AVG placement. Implementing RA may increase AVF utilization and enhance patient outcomes in hemodialysis access surgery.
MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics
Greenberg, Steven M. , Albert, Marylin S., An, Hongyu , Arfanakis, Konstantinos , Evia, Arnold M , Caprihan, Arvind , Ford, Andria L. , Fornage, Myriam , Day, Gregory S. , Hinman, Jason D. , Kashani, Amir H. , Kramer, Joel H. , Lachner, Christian , Maillard, Pauline , Petersen, Ronald C. , Ringman, John M. , Savitz, Sean I. , Windham, B. Gwen, Zhang, Rong , Tuozzo, Carissa , Singh, Herpreet , Moy, Sue, Okey‐Ewurum, Vilma , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya, Helmer, Karl G. , Wruck, Lisa , Corriveau, Roderick A. , Jicha, Gregory A , Kashani, Amir H , Lachner, Christian , Lee, Jin-Moo , Liu, Peiying , Lu, Hanzhang , Maillard, Pauline , Petersen, Ronald C , Psaty, Bruce M , Ringman, John M , Rosenberg, Gary A. , Satizabal, Claudia L , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J J , Wilcock, Donna M , Tuozzo, Carissa , Singh, Herpreet , Okey-Ewurum, Vilma , Page, Courtney B , Mulder, Hillary , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya , Helmer, Karl G , Wruck, Lisa M , Day, Gregory S , Jicha, Gregory A. , Lee, Jin‐Moo , Liu, Peiying , Lu, Hanzhang , Psaty, Bruce M. , Satizábal, Claudia L. , Schneider, Julie A. , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J.J. , Wilcock, Donna M. , Mulder, Hillary , Schwab, Kristin

Mayo Clinic

Annals of Neurology | September 22, 2025 | Volume: 99 | Issue: 2 | Pages: 449-458

10.1002/ana.78040 | PMID 40977537 Get It

Objective To establish a framework for validating candidate biomarkers of cerebral small vessel diseases (SVD) associated with cognitive impairment and characterize individuals enrolled by the MarkVCID2 consortium under this framework. Methods Participants age 60 to 90 years were enrolled across 17 MarkVCID2 sites. Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impairment, subjective cognitive decline), defined risk factors (diabetes mellitus, advanced hypertension), and Black/African American, White, and Hispanic/Latino subgroups. Enrolled participants underwent baseline visits that included cognitive testing, multimodal magnetic resonance imaging (MRI), and biofluid collection. Provisional risk for SVD‐related cognitive decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors. Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate‐to‐severe white matter hyperintensities, microbleeds, or lacunes on baseline MRI. Results MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non‐Hispanic Black. Among enrollees, 44.8% were provisionally designated high‐risk. After baseline MRI, 48.5% were categorized as adjudicated high‐risk status, with substantial recategorization both from low‐ to high‐risk (primarily because of MRI lesions without SVD risk factors) and high‐ to low‐risk (primarily suspected cognitive impairment at screening not confirmed by baseline testing). Interpretation MarkVCID2 baseline data indicate successful enrollment of diverse individuals enriched in factors associated with SVD‐related cognitive decline. Changes over 3 years of longitudinal follow‐up will be analyzed to validate the candidate biomarkers for 2 projected contexts of use: subject selection (identifying likelihood of future SVD progression) and study outcome (efficiently measuring SVD progression). ANN NEUROL 2026;99:449–458
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study
Hussain, Yessar, Malhotra, Saurabh , Sperry, Brett W. , Shu, Francy , Ananthasubramaniam, Karthikeyan , Desai, Urvi , Egolum, Ugochukwu , Fernandez, Joel , Freimer, Miriam , Mauricio, Elizabeth A. , Quan, Dianna , Small, Roy S., Capocelli, Kelley E. , Roblin, Steven, Bender, Shaun , Jay, Patrick Y. , Yureneva, Elena, Zolty, Ronald , Mauricio, Elizabeth A. , Capocelli, Kelley , Sperry, Brett W

Mayo Clinic

Annals of Medicine | September 20, 2025 | Volume: 57 | Issue: 1 | Pages: No page available

10.1080/07853890.2025.2537347 | PMID 40974604 Get It

Abstract B065: Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type
Hegde, Apurva M. , Garcia-Masnfield, Krystine, Alcantara, Marice , ROSE, D. L. , Halperin, Rebecca F. , David‐Dirgo, Victoria , Facista, Salvatore , Moore, Rayvon , Kofman, Rochelle , Jensen, Zoe N. , Zismann, Victoria , Hendricks, William P.D. , Huntsman, David G. , Rodrı́guez-Rodrı́guez, Lorna , Weissman, Bernard E. , Trent, Jeffrey M. , Pirrotte, Patrick , Raupach, Elizabeth A. , Rose, David, Orlando, Krystal A. , Lang, Jessica, Sharma, Ritin , Karnezis, Anthony N. , Wang, Yemin , Bennett, Lynda , Whitsett, Timothy G. , Kortylewski, Marcin T.

Mayo Clinic

Cancer Research | September 19, 2025 | Volume: 85 | Issue: 18_Supplement | Pages: B065-B065

10.1158/1538-7445.ovarian25-b065 Get It

Abstract Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. Here, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared to normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune reactive tumor microenvironment. Mutations in several SWI/SNF subunits were associated with higher rates of outlier retained introns across tumor types in TCGA data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention. Distinct protein-protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Further, SWI/SNF localized to genes which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFa and INFb in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to intron retention. Furthermore, T cell activation by novel peptides encoded by these tumor-specific splicing events suggests intron retention could be a source of tumor-associated antigens in SCCOHT. Citation Format: Elizabeth Raupach, Apurva Hegde, Krystine Garcia-Masnfield, Marice Alcantara, David Rose, Rebecca Halperin, Krystal Orlando, Jessica Lang, Ritin Sharma, Victoria David-Dirgo, Salvatore Facista, Rayvon Moore, Rochelle Kofman, Zoe Jensen, Victoria Zismann, Anthony Karnezis, Yemin Wang, Lynda Bennett, Timothy Whitsett, Marcin Kortylewski, William Hendricks, David Huntsman, Lorna Rodriguez-Rodriguez, Bernard Weissman, Jeffrey Trent, Patrick Pirrotte. Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; 2025 Sep 19-21; Denver, CO. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl):Abstract nr B065.
Stereotactic Radiosurgery Versus Observation in Small- and Medium-Sized Vestibular Schwannoma Patients With Normal Hearing: A Retrospective International Multicenter Study
Hajikarimloo, Bardia , Ishaque, Mariam , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L. , Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Tos, Salem M , Mantziaris, Georgios , Abou‐Al‐Shaar, Hussam , Peker, Selçuk , Samancı, Yavuz , Mathieu, David , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Warnick, Ronald E. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | September 16, 2025 | Volume: 98 | Issue: 4 | Pages: 887-894

10.1227/neu.0000000000003734 | PMID 40956102 Get It

BACKGROUND AND OBJECTIVES: The therapeutic approach for small- and medium-sized vestibular schwannoma (VS) with normal hearing function remains controversial, with limited comparative data regarding hearing outcomes after stereotactic radiosurgery (SRS) or observation (OBS). We evaluated the serviceable hearing preservation, loss of American Academy of Otolaryngology-Head and Neck Surgery class A hearing, and tumor control (TC) across individuals with Koos grade I and II VSs and normal hearing at presentation who underwent SRS or OBS. METHODS: In this multicenter international study, we retrospectively analyzed the hearing, radiological, and neurological outcomes of patients who underwent SRS (SRS group) or OBS (OBS group). The cohorts were matched using propensity scores based on age, sex, tumor volume, pure-tone average, and speech discrimination score at a 1:1 ratio without replacement. RESULTS: After matching, each group comprised 57 patients. The median follow-up was 49 and 37 months for the SRS and the OBS groups, respectively ( P = .3). The 5- and 9-year serviceable hearing preservation rates in the SRS group were 76.2% and 42.4% vs 56.1% and 16.8% in the OBS group ( P = .17). Class A preservation occurred in 57.9% (33/57) of the SRS and 52.6% (30/57) of the OBS cohorts ( P = .70). Regarding the TC rates, SRS was associated with significantly higher TC rates ( P < .0001). CONCLUSION: We found that SRS is significantly superior regarding TC and provided noninferior hearing outcomes compared with OBS in VS patients with American Academy of Otolaryngology-Head and Neck Surgery class A hearing at presentation. Therefore, we suggest performing SRS in individuals with VS and normal hearing function.